Publications by authors named "P C Nett"
Challenges in multi-centric generalization: phase and step recognition in Roux-en-Y gastric bypass surgery.
Int J Comput Assist Radiol Surg
November 2024
Article Synopsis
- Most studies on AI for surgical activity recognition have focused narrowly on single activities and small data sets, raising questions about their general applicability across different surgical centers.
- This research introduces a comprehensive dataset called MultiBypass140, which includes 140 laparoscopic Roux-en-Y gastric bypass videos from two different hospitals, annotated by professional surgeons to enhance training and evaluation accuracy.
- Findings indicate that training AI models on varied data from multiple centers significantly enhances their performance and generalization, highlighting the limitations of mono-centric training approaches.
Importance: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality after bariatric surgery. Clinical end point studies on thromboprophylaxis with direct oral anticoagulants in patients undergoing bariatric surgery are lacking.
Objective: To assess the efficacy and safety of a prophylactic dose of 10 mg/d of rivaroxaban for both 7 and 28 days after bariatric surgery.
Sleeve gastrectomy (SG) is the most frequently performed bariatric surgical intervention worldwide. Gastroesophageal reflux disease (GERD) is frequently observed after SG and is a relevant clinical problem. This prospective study investigated the gastroesophageal junction (GEJ) and pyloric sphincter by impedance planimetry (EndoFlip) and their association with GERD at a tertiary university hospital center.
View Article and Find Full Text PDFRandomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.
Diabetes Technol Ther
July 2023
To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB). Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT).
View Article and Find Full Text PDF